Search

MF-300

As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983] … MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.

Diethylpropion

(From AMA Drug Evaluations Annual, 1994, p2290)

Mafenide

It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

Corticosterone

(From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437) … An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

Vedolizumab

[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

Pheniprazine

Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis. … Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s.

Soy isoflavones

Deucravacitinib

[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … cholesterol and triglyceride levels and liver and kidney dysfunction.

Padeliporfin

Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. … [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]

SR-123781A

SR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).